Cannabidiol (CBD) may be beneficial in the treatment of psychiatric/cognitive symptoms associated with neurodegeneration, according to a new study.
The study, published by the journal Frontiers in Pharmacology, was also published online by the U.S. National Institute of Health.
“Beneficial effects of cannabidiol (CBD) have been described for a wide range of psychiatric disorders, including anxiety, psychosis, and depression”, begins the study’s abstract. “The mechanisms responsible for these effects, however, are still poorly understood. Similar to clinical antidepressant or atypical antipsychotic drugs, recent findings clearly indicate that CBD, either acutely or repeatedly administered, induces plastic changes.”
For example, “CBD attenuates the decrease in hippocampal neurogenesis and dendrite spines density induced by chronic stress and prevents microglia activation and the decrease in the number of parvalbumin-positive GABA neurons in a pharmacological model of schizophrenia.”
More recently, the study notes, “it was found that CBD modulates cell fate regulatory pathways such as autophagy and others critical pathways for neuronal survival in neurodegenerative experimental models, suggesting the potential benefit of CBD treatment for psychiatric/cognitive symptoms associated with neurodegeneration.” These changes are possibly associated with CBD’s “beneficial effects in psychiatric disorders”.
The full study can be found by clicking here.